Okogen Advances Acute Infectious Conjunctivitis Treatment with Regulatory Submission and New CMO

Okogen Inc. has taken a significant step forward in addressing acute infectious conjunctivitis (AIC) by submitting a regulatory application to the Central Drugs Standard Control Organization (CDSCO) in India for its Phase IIb clinical trial, known as the Emerald Study. The submission coincides with the appointment of Dr. David A. Hollander as the company's new Chief Medical Officer, reinforcing its commitment to developing innovative eyecare solutions.

The Emerald Study, scheduled during the 2025 Monsoon Season when conjunctivitis rates are highest, aims to evaluate the individual components of OKG-0303, a triple-combination eyedrop designed to combat both bacterial and viral forms of conjunctivitis. This research represents a critical advancement in addressing a significant healthcare challenge with substantial market potential.

The current conjunctivitis market is valued at $4.2 billion annually, with projections indicating growth to over $6 billion by 2031. Notably, there are currently no approved treatments for adenoviral conjunctivitis, which comprises more than 90% of viral ocular infections. This gap in medical treatment underscores the importance of Okogen's research and development efforts.

Dr. Hollander brings extensive experience to the role, having previously served as Chief Medical Officer at Revance and held leadership positions at Aerie Pharmaceuticals and Allergan. His expertise in drug development and regulatory affairs is expected to be instrumental in advancing Okogen's clinical development strategy.

Joshua Moriarty, CEO of Okogen, emphasized the significance of these milestones, highlighting the company's commitment to challenging conventional approaches to AIC treatment. The regulatory submission represents a crucial step toward a potential data readout in the fourth quarter of 2025.

Beyond the clinical trial, Okogen is simultaneously developing an AI-powered evaluation tool aimed at improving patient care and diagnostic accuracy. The company's innovative approach addresses the complex challenges of diagnosing and treating acute infectious conjunctivitis, which can spread rapidly in school and workplace environments.

The Emerald Study's timing during the monsoon season provides a strategic opportunity to collect comprehensive data on AIC transmission and treatment efficacy. By focusing on this critical period, Okogen aims to generate meaningful insights that could transform the management of this widespread medical condition.